Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study
https://doi.org/10.21886/2219-8075-2017-8-4-74-81
Abstract
Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis. Materials and methods: a prospective cohort clinical trial involved 50 patients with HCV (including 30 patients with compensated cirrhosis of the liver, class A in Child-Pugh), caused by genotype 1b. All patients received asunaprevir in a dose of 100 mg twice a day in combination with daclatasvir 60 mg once a day. Th e duration of the treatment course was 24 weeks. Th e effi cacy criterion was the undetectable level of HCV RNA 24 weeks aft er the end of antiviral therapy (SVR24). Results: at the end of the 4th week of treatment, aviremia was achieved in 92% of patients. Th e incidence of SVR24 in previously untreated patients was 90%, in the group of patients who did not respond to previous therapy with pegylated interferon-interferon with ribavirin- 86.9%. Conclusion: Th e combination of asunaprevir with daclatasvir is highly eff ective and provides a sustained virologic response in 86-90% of cases. A low incidence of adverse events (8%) demonstrates a favorable safety profi le of this treatment regimen.
About the Authors
Elena B. Romanova
NA Semashko the city hospital number 1
Russian Federation
PhD, associate professor, doctor of infectious diseases department No.4
Competing Interests:
Russian Federation
PhD, associate professor, doctor of infectious diseases department No.4
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов.
Yuri M. Ambalov
Rostov State Medical University
Russian Federation
PhD, Professor, Head of the Department infectious diseases Rostov State Medical University
Russian Federation
PhD, Professor, Head of the Department infectious diseases Rostov State Medical University
Dmitry V. Sizyakin
NA Semashko the city hospital number 1
Russian Federation
PhD, Professor, chief physician of the NA Semashko city hospital number 1
Russian Federation
PhD, Professor, chief physician of the NA Semashko city hospital number 1
Irina Y. Khomenko
NA Semashko the city hospital number 1
Russian Federation
Candidate of Medical Sciences, Head of infectious diseases department No.4
Russian Federation
Candidate of Medical Sciences, Head of infectious diseases department No.4
Oleg I. Khomenko
NA Semashko the city hospital number 1
Russian Federation
Candidate of Medical Sciences, doctor of infectious diseases department No.4
Russian Federation
Candidate of Medical Sciences, doctor of infectious diseases department No.4
Karina R. Titiryan
Rostov State Medical University
Candidate of Medical Sciences, Teaching Assistant, Department of infection diseases
Candidate of Medical Sciences, Teaching Assistant, Department of infection diseases
References
1. Chulanov VP, Pimenov NN, Mamonova NA, Sagalova OI, Shestakova IV, Pokrovsky VI Chronic hepatitis C as a public health problem in Russia today and tomorrow. Th erapeutic archive. 2015;87(11):5-10. doi: 10.17116/terarh201587115-10
2. Federal Service of State Statistics [Electronic resource]. Available at: http://www.gks.ru/. Accessed November 7, 2017
3. Esaulenko EV, Sukhoruk AA, Gerasimova OA Th e natural course of chronic hepatitis C aft er liver transplantation. Infectious diseases. 2014;12(1):22-26.
4. Nikitin IG, Baikova IE, Gogova LM, Volynkina VM, Kislyakov VA Boceprevir: new opportunities for antiviral treatment of chronic hepatitis C. Th erapeutic archive. 2013;85(2):76-84. doi: 10.17116 / terarh201587115-10
5. EASL Recommendations on Treatment of Hepatitis C 2016. European Association for the Study of the liver. J. Hepatology. 2017;66(1):153–194. doi: 10.1016 / j.hep.2016 / 09/001.
6. Batskikh S.N. Nezinterferonovaya therapy of chronic hepatitis C: a change in the drug or a new paradigm of treatment? Ros. Journal gastroenterology, hepatology, coloproctology. 2014;24(4):23-31.
7. McPhee F., Sheaft er A.K., Friborg J., Hernandez D., Falr P., Znai G. et al. Preclinical Profi le and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS650032). Antimicrob. Agents Chemother. 2012;56(10):5387-5396. doi: 10.1128/AAC.01186-12
8. Maevskaya MV, Zharkova MS, Ivashkin VT Th e inhibitor of the NS5A replication complex daklatasvir is based on the non-interferon therapy of chronic hepatitis C. Ros. Journal gastroenterology, hepatology, coloproctology. 2015;(4):42-48.
9. Kumada H., Suzuki Y., Ikeda K., Toyota J., Karino Y., et al. Daclatasvir for asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083-2091. doi: 10.1002/hep.27113
10. Manns M., Pol S., Jacobson I. M., Marcellin P., Gordon S.C., Peng C.Y. et al. HALLMARK-DUAL Study Team. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results. J.Hepatology. 2014;60(1):S524-S525. doi: 10.1016/S0168-8278(14)61461-6
11. Lok A.S., Gardiner D.F., Hezode C., Lawitz E.J., Bourliere M., Everson G.T. et al. Randomizide trial of daclatasvir and asunaprevir with or without PegIFN / RBV for hepatitis C virus genotype 1 nullresponders. Journal of Hepatology. 2014;60:490-499. doi: 10.1016 / j.jhep.2013.10.019.
Review
For citations:
Romanova E.B., Ambalov Yu.M., Sizyakin D.V., Khomenko I.Y., Khomenko O.I., Titiryan K.R. Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study. Medical Herald of the South of Russia. 2017;8(4):74-81. (In Russ.) https://doi.org/10.21886/2219-8075-2017-8-4-74-81
Views:
631
Email this article 